Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy Planning, Computer-Assisted | 27 | 2022 | 64 | 6.770 |
Why?
|
| Radiotherapy Dosage | 36 | 2023 | 102 | 4.110 |
Why?
|
| Radiometry | 19 | 2023 | 44 | 2.950 |
Why?
|
| Radiotherapy, Intensity-Modulated | 13 | 2021 | 35 | 2.840 |
Why?
|
| Phantoms, Imaging | 18 | 2021 | 98 | 2.720 |
Why?
|
| Cone-Beam Computed Tomography | 7 | 2018 | 40 | 2.120 |
Why?
|
| Proton Therapy | 11 | 2023 | 28 | 2.070 |
Why?
|
| Electrons | 5 | 2022 | 26 | 2.050 |
Why?
|
| Algorithms | 15 | 2022 | 422 | 1.940 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2018 | 58 | 1.760 |
Why?
|
| Monte Carlo Method | 10 | 2023 | 61 | 1.650 |
Why?
|
| Radiosurgery | 8 | 2018 | 82 | 1.360 |
Why?
|
| Models, Theoretical | 4 | 2018 | 130 | 1.350 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2018 | 247 | 1.250 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 467 | 1.130 |
Why?
|
| Brain Neoplasms | 7 | 2016 | 297 | 1.120 |
Why?
|
| Radiotherapy | 3 | 2013 | 39 | 1.070 |
Why?
|
| Brachytherapy | 5 | 2022 | 50 | 1.050 |
Why?
|
| Respiratory Mechanics | 3 | 2015 | 16 | 1.010 |
Why?
|
| Quality Assurance, Health Care | 4 | 2014 | 62 | 0.960 |
Why?
|
| Prostatic Neoplasms | 5 | 2014 | 271 | 0.890 |
Why?
|
| Protons | 5 | 2023 | 54 | 0.840 |
Why?
|
| Neoplasms | 6 | 2018 | 769 | 0.830 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 98 | 0.740 |
Why?
|
| Patient Positioning | 3 | 2016 | 22 | 0.730 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 343 | 0.690 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2016 | 128 | 0.690 |
Why?
|
| Immobilization | 3 | 2010 | 15 | 0.680 |
Why?
|
| Humans | 46 | 2022 | 27175 | 0.650 |
Why?
|
| Radiotherapy Setup Errors | 2 | 2016 | 5 | 0.650 |
Why?
|
| Artifacts | 4 | 2014 | 49 | 0.630 |
Why?
|
| Thorax | 1 | 2018 | 28 | 0.590 |
Why?
|
| Models, Statistical | 3 | 2017 | 122 | 0.580 |
Why?
|
| Computer Simulation | 6 | 2021 | 221 | 0.540 |
Why?
|
| Radiotherapy, Conformal | 4 | 2012 | 15 | 0.530 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 752 | 0.500 |
Why?
|
| Models, Biological | 3 | 2016 | 448 | 0.480 |
Why?
|
| Sensitivity and Specificity | 7 | 2014 | 510 | 0.480 |
Why?
|
| Glottis | 1 | 2014 | 4 | 0.470 |
Why?
|
| Laryngeal Neoplasms | 1 | 2014 | 8 | 0.470 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2011 | 4 | 0.450 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 28 | 0.450 |
Why?
|
| Scattering, Radiation | 4 | 2018 | 28 | 0.430 |
Why?
|
| Gamma Rays | 1 | 2013 | 28 | 0.410 |
Why?
|
| Motion | 5 | 2014 | 25 | 0.400 |
Why?
|
| Tumor Burden | 1 | 2012 | 108 | 0.400 |
Why?
|
| Heavy Ion Radiotherapy | 1 | 2012 | 1 | 0.390 |
Why?
|
| Iridium Radioisotopes | 1 | 2010 | 3 | 0.360 |
Why?
|
| Software | 1 | 2012 | 121 | 0.350 |
Why?
|
| Optical Phenomena | 1 | 2010 | 5 | 0.350 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 30 | 0.350 |
Why?
|
| Head | 1 | 2010 | 16 | 0.350 |
Why?
|
| Breast | 1 | 2010 | 54 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 3 | 2021 | 84 | 0.340 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2010 | 2 | 0.340 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 65 | 0.330 |
Why?
|
| Heart | 1 | 2010 | 221 | 0.320 |
Why?
|
| Lung | 2 | 2016 | 360 | 0.310 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 107 | 0.300 |
Why?
|
| Ultrasonography | 1 | 2009 | 229 | 0.300 |
Why?
|
| X-Ray Film | 3 | 2013 | 10 | 0.280 |
Why?
|
| Radiation Dosage | 4 | 2018 | 53 | 0.270 |
Why?
|
| Catheterization | 1 | 2005 | 50 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 156 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 447 | 0.240 |
Why?
|
| Male | 17 | 2020 | 13034 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2019 | 2464 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 285 | 0.200 |
Why?
|
| Photons | 1 | 2022 | 27 | 0.190 |
Why?
|
| Hippocampus | 2 | 2015 | 187 | 0.190 |
Why?
|
| Movement | 2 | 2018 | 95 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 1943 | 0.170 |
Why?
|
| Middle Aged | 11 | 2019 | 6918 | 0.170 |
Why?
|
| Aged | 10 | 2019 | 5232 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2012 | 2289 | 0.160 |
Why?
|
| Radiography | 2 | 2010 | 201 | 0.160 |
Why?
|
| Conjunctival Neoplasms | 1 | 2018 | 6 | 0.160 |
Why?
|
| Radiation Tolerance | 2 | 2010 | 32 | 0.160 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2018 | 9 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 61 | 0.150 |
Why?
|
| Neutrons | 1 | 2018 | 4 | 0.150 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 12 | 0.150 |
Why?
|
| Radiation Protection | 1 | 2018 | 18 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 463 | 0.150 |
Why?
|
| Female | 11 | 2022 | 14658 | 0.140 |
Why?
|
| Prognosis | 4 | 2018 | 762 | 0.140 |
Why?
|
| Water | 2 | 2021 | 131 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2022 | 191 | 0.130 |
Why?
|
| Radiation Monitoring | 2 | 2018 | 8 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2014 | 81 | 0.120 |
Why?
|
| Semiconductors | 1 | 2014 | 4 | 0.120 |
Why?
|
| Calibration | 1 | 2014 | 28 | 0.110 |
Why?
|
| Rectum | 2 | 2022 | 50 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 36 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 212 | 0.110 |
Why?
|
| Film Dosimetry | 1 | 2012 | 8 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 12 | 0.090 |
Why?
|
| Orbital Pseudotumor | 1 | 2010 | 2 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 8 | 0.090 |
Why?
|
| Parotid Gland | 1 | 2010 | 6 | 0.090 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2010 | 22 | 0.090 |
Why?
|
| Quality Control | 1 | 2010 | 20 | 0.090 |
Why?
|
| Organs at Risk | 2 | 2020 | 4 | 0.090 |
Why?
|
| Brain | 1 | 2015 | 710 | 0.090 |
Why?
|
| Radiobiology | 1 | 2010 | 5 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2010 | 4 | 0.090 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 9 | 0.080 |
Why?
|
| Adult | 7 | 2019 | 7510 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 129 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2011 | 93 | 0.080 |
Why?
|
| Surface Properties | 1 | 2010 | 132 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 26 | 0.080 |
Why?
|
| Prostheses and Implants | 1 | 2009 | 27 | 0.080 |
Why?
|
| Oxygen | 1 | 2010 | 230 | 0.080 |
Why?
|
| Densitometry | 1 | 2009 | 9 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 75 | 0.080 |
Why?
|
| Skin | 1 | 2010 | 140 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2010 | 181 | 0.080 |
Why?
|
| United States | 1 | 2014 | 2063 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 32 | 0.070 |
Why?
|
| Cognition | 1 | 2010 | 299 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2008 | 56 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 395 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 188 | 0.070 |
Why?
|
| Curcumin | 1 | 2008 | 67 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2005 | 76 | 0.060 |
Why?
|
| Cyclotrons | 1 | 2023 | 11 | 0.050 |
Why?
|
| Needles | 1 | 2022 | 26 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 659 | 0.050 |
Why?
|
| Retreatment | 2 | 2010 | 12 | 0.050 |
Why?
|
| Normal Distribution | 1 | 2020 | 6 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2010 | 74 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 293 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2019 | 12 | 0.040 |
Why?
|
| Workflow | 1 | 2018 | 25 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 70 | 0.040 |
Why?
|
| Uncertainty | 1 | 2016 | 23 | 0.030 |
Why?
|
| Young Adult | 2 | 2010 | 2636 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 2996 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2012 | 11 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 16 | 0.020 |
Why?
|
| Particle Accelerators | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 119 | 0.020 |
Why?
|
| Graves Ophthalmopathy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Dry Eye Syndromes | 1 | 2010 | 5 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 50 | 0.020 |
Why?
|
| Anaerobiosis | 1 | 2010 | 90 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 94 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 86 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 317 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 490 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 333 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 451 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 312 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 990 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 42 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 207 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 538 | 0.020 |
Why?
|
| Oklahoma | 1 | 2011 | 977 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 265 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 188 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 407 | 0.020 |
Why?
|
| DNA | 1 | 2008 | 365 | 0.020 |
Why?
|
| Peptides | 1 | 2008 | 283 | 0.020 |
Why?
|
| Apoptosis | 1 | 2008 | 738 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1271 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 4472 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 10082 | 0.010 |
Why?
|